Skip to content
vaccines hero image
vaccines hero image

Vaccines

Vaccines contain antigenic substances capable of inducing immunity against an infective agent or toxin.

They are frequently administered prophylactically but are increasingly being researched and developed in a therapeutic context (eg cancer vaccines which are designed to equip a patient’s immune system to treat an existing cancer).

While the global market for vaccines is less than 3% of the total pharmaceuticals market, World Health Organization research suggests that over the next few years, the vaccine market will enjoy a growth rate of 10% to 15% per year versus the 5% to 7% seen in the overall market.

To take a share of this expanding market, companies must navigate a number of challenges. The assessment, licensing and control of vaccines (which are biological medicinal products) occurs in an environment of rapid innovation and complex quality concerns. Our deep experience of vaccines, combined with the fact that our team includes lawyers with degrees in relevant scientific areas (molecular biology, biochemistry, genetics etc), enables us to quickly grasp evolving issues and technical concepts and provide nuanced and tailored advice.

We are trusted by many of the world’s leading vaccine companies to help them navigate all stages of the vaccine lifecycle. Our clients include Merck, GlaxoSmithKline, Johnson & Johnson, Pfizer and Novartis.

News & insights

Bird's eye view of a major intersection and suspension bridge at night

News: 10 JULY 2020

Allen & Overy advises on Immunotech Biopharm’s global offering and listing on the Hong Kong Stock Exchange

Allen & Overy has advised the joint sponsors on the global offering and listing of shares of Immunotech Biopharm Ltd (Immunotech Biopharm) on the Hong Kong Stock Exchange under Chapter 18A of the…

Read more
A drop of liquid falling into a test tube

Publications: 08 JULY 2020

Pipeline gaps and digital will drive life sciences deals

Often seen as a safe haven sector in times of crisis, the life sciences have not only been centre stage during the Covid-19 coronavirus crisis but are riding it out well.

Read more

Publications: 24 JUNE 2020

Covid-19 coronavirus: How the global life sciences sector is responding to the pandemic

Our life sciences sector team reviews the steps taken by the industry and public bodies to minimise disruption to regular business activities and to promote the development and supply of medicines and…

Read more

Publications: 24 JUNE 2020

Changes to UK merger control: public health emergencies and national security

On 21 June the UK Government announced plans to introduce a new public interest consideration to the UK merger control regime: public health emergency. It also announced a proposal to expand its…

Read more

Download our sector brochure

Life sciences A&O red molecules

An insight in to our Life Science and Healthcare sector 2020

Our global Life Sciences and Healthcare sector comprises a multi-disciplinary team. We act for companies and their investors across the industry, including in the pharmaceuticals, biotech, animal health, consumer health, med tech, and diagnostics sectors.